Patents by Inventor Ulrich Emde

Ulrich Emde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYLQUINAZOLINES
    Publication number: 20220117970
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: May 28, 2021
    Publication date: April 21, 2022
    Inventors: Thomas FUCHSS, Ulrich EMDE, Hans-Peter BUCHSTALLER, Werner MEDERSKI
  • Arylquinazolines
    Patent number: 11065253
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: July 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITION OF L-EPINEPHRINE
    Publication number: 20210205238
    Abstract: The invention relates to injectable pharmaceutical compositions comprising epinephrine, an antioxidant selected from the group consisting of sodium metabisulfite, sodium sulfite and sodium bisulfite, tartrate, a tonicity regulating agent, EDTA or Na2EDTA*2H2O and pH 3.0-4.5.
    Type: Application
    Filed: October 8, 2018
    Publication date: July 8, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Steffen AUGUSTIN, Thomas Artur Hendrik HERBST, Ulrich EMDE
  • ARYLQUINAZOLINES
    Publication number: 20200069690
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 5, 2020
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Modular dental tool and docking station
    Patent number: 10434024
    Abstract: A modular dental system, methods for controlling a modular dental tool, a dental system, a control module, and a treatment unit. In one embodiment, the modular dental system includes a modular dental system including a control module and a battery module. The control module includes a first end, a second end, a control sub-system, and a charging sub-system. The control sub-system is configured to communicatively couple to an attachment, detect an attachment identifier associated with the attachment when the attachment is removably attached to the first end of the control module, and control the attachment based on the attachment identifier. The battery module is configured to removably attach to the second end of the control module.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: October 8, 2019
    Assignees: KAVO DENTAL TECHNOLOGIES, LLC, KALTENBACH & VOIGT GMBH
    Inventors: Robert Thomas St. Louis, Michael Carl Dunaway, Frank Ulrich Emde, Amod Ashok Kher, Tyler Ray Harper, Nathan Lamb Shippee, Johannes Sauter, Patrick Niederreuter
  • Arylquinazolines
    Patent number: 10383874
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 20, 2019
    Assignee: Merk Patent GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • ARYLQUINAZOLINES
    Publication number: 20190142833
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 16, 2019
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Arylquinazolines
    Patent number: 10172859
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • MODULAR DENTAL TOOL AND DOCKING STATION
    Publication number: 20180042802
    Abstract: A modular dental system, methods for controlling a modular dental tool, a dental system, a control module, and a treatment unit. In one embodiment, the modular dental system includes a modular dental system including a control module and a battery module. The control module includes a first end, a second end, a control sub-system, and a charging sub-system. The control sub-system is configured to communicatively couple to an attachment, detect an attachment identifier associated with the attachment when the attachment is removably attached to the first end of the control module, and control the attachment based on the attachment identifier. The battery module is configured to removably attach to the second end of the control module.
    Type: Application
    Filed: August 15, 2016
    Publication date: February 15, 2018
    Inventors: Robert Thomas St. Louis, Michael Carl Dunaway, Frank Ulrich Emde, Amod Ashok Kher, Tyler Ray Harper, Nathan Lamb Shippee, Johannes Sauter, Patrick Niederreuter
  • ARYLQUINAZOLINES
    Publication number: 20170290836
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Arylquinazolines
    Patent number: 9732094
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: August 15, 2017
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • ARYLQUINAZOLINES
    Publication number: 20160083401
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: May 8, 2014
    Publication date: March 24, 2016
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Ulrich EMDE, Hans-Peter BUCHSTALLER, Werner MEDERSKI
  • Morpholinylbenzotriazines for use in cancer therapy
    Patent number: 9187469
    Abstract: The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into a salt thereof.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: November 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller
  • Quinoxalines derivatives and pharmaceutical compositions and kits
    Patent number: 8895559
    Abstract: A variety of specific compounds within the scope of formula I which are useful as PI3K inhibitors and can be employed for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours, and pharmaceutical compositions and kits containing said specific compounds.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: November 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Ulrich Emde, Hans-Peter Buchstaller, Christina Esdar, Oliver Poeschke
  • MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY
    Publication number: 20140275072
    Abstract: The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into a salt thereof.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 18, 2014
    Applicant: Merck Patent GmbH
    Inventors: Werner Mederski, Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller
  • Pyridinylimidazolone derivatives for the inhibition of PI3 kinases
    Patent number: 8802866
    Abstract: Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Patent GmbH
    Inventors: Ulrich Emde, Hans Peter Buchstaller, Markus Klein, Christina Esdar, Joerg Bomke
  • Pyrazolopyrimidine derivatives
    Patent number: 8741896
    Abstract: Compounds of the formula (I), in which X, R1 and R2 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: June 3, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Peter Buchstaller, Ulrich Emde, Markus Klein, Christina Esdar, Joerg Bomke
  • QUINOXALINE DERIVATIVES
    Publication number: 20130217670
    Abstract: Compounds of the formula I in which R, R1 and R2 have the meanings indicated in Claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.
    Type: Application
    Filed: September 22, 2011
    Publication date: August 22, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Markus Klein, Ulrich Emde, Hans-Peter Buchstaller, Christina Esdar, Oliver Poeschke
  • Beta-amino acid derivatives for treatment of diabetes
    Patent number: 8431602
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R2?, R2?, R3, R4, R5, R6, R7 and R8 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 30, 2013
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Stefan Bender, Lars Thore Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2
    Patent number: 8383838
    Abstract: The present invention relates to novel compounds of general formula (I) and uses thereof.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: February 26, 2013
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Christoph Saal, Lars Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon